Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enekinragene inzadenovec (GQ Bio Therapeutics)
- Development stage
- Unknown
- Lead developer
- Pacira BioSciences
- Modality
- Gene Therapies
- Administration
- Intraarticular
01
Overview
Enekinragene inzadenovec (PCRX-201, formerly FX201 or HCAd-IL-1RA) is an investigational, locally administered gene therapy designed for the treatment of osteoarthritis (OA) of the knee. It consists of a high-capacity, non-replicating adenovirus serotype 5 (Ad5) vector encoding human interleukin-1 receptor antagonist (IL-1Ra) under the control of an inflammation-inducible nuclear factor kappa B (NF-κB) promoter. This design allows for 'on-demand' production of IL-1Ra in response to joint inflammation, blocking the interleukin-1 (IL-1) pathway to reduce chronic inflammation, alleviate pain, and potentially modify disease progression. Originally developed at Baylor College of Medicine and GQ Bio Therapeutics (formerly GeneQuine Biotherapeutics), the asset was licensed by Flexion Therapeutics (later acquired by Pacira BioSciences). It is currently in Phase 2 clinical development.
- Other names
- humantakinogene hadenovecinterleukin-1 receptor antagonist gene therapyinterleukin1 receptor antagonist gene therapyinterleukin 1 receptor antagonist gene therapy
02
Targets
IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on enekinragene inzadenovec (GQ Bio Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enekinragene inzadenovec (GQ Bio Therapeutics).